What the trials counted as intolerance

The uncomfortable finding underneath all of this is that the tolerability ceiling varies severalfold between people and nothing measurable in advance predicts where an individual sits. Sex, age, baseline weight and diabetes status shift the average modestly. None of them narrows the distribution enough to be useful for one person. The ceiling is discovered by approaching it, which is a reasonable procedure and an unsatisfying one, and it is the reason this class cannot be dosed by algorithm.

The dose is the intervention with the best evidence

Symptom burden in this class is dose-dependent and attenuates with time at a fixed dose. It follows that the interventions with the strongest support are the ones that act on those two variables: hold the current dose rather than escalating, extend the interval before the next increment, or step back one rung and approach it again later. All three are visible in the trial protocols, which permitted delayed escalation for tolerability, and all three address cause rather than sensation.

This is not a fashionable position, because it is undramatic and it involves accepting a slower ascent. It is nonetheless where the effect sizes are. A person struggling at 10 mg who holds for eight weeks is doing something the tolerability data supports. A person struggling at 10 mg who adds an antiemetic and escalates on schedule is managing a symptom while increasing its cause.

There is a cost to the slower route, and it should be stated: later arrival at target exposure and therefore later arrival at the efficacy plateau. Since the plateau in the long trials sits beyond week sixty, adding a month or two to escalation is a small fraction of the course, while discontinuation costs the whole of it.¹

A strict definition, and four questions

An effect is dose-limiting when it prevents adequate intake or hydration, prevents ordinary activity, prevents sleep on a sustained basis, or creates a risk of its own. That is a narrower bar than discomfort and a broader one than emergency.

Four questions locate it. Can fluids be kept down over a full day? Is food intake adequate in volume and composition, or has it collapsed to whatever is tolerable? Has ordinary activity — work, exercise, leaving the house — been given up? And is the symptom improving, static or worsening across a week at an unchanged dose?

The last question is the most diagnostic and the least asked. Symptoms in this class typically improve across weeks at a fixed dose. A symptom that is worsening at an unchanged dose is behaving unlike the expected pattern, and that alone warrants assessment rather than endurance. Conversely, a symptom that is clearly improving week over week is following the documented trajectory, which is information a person can act on.

Who stops, and why the trial figures understate it

Discontinuation for adverse events ran to roughly four and a half per cent on top-dose semaglutide and between four and seven per cent across the tirzepatide dose range, against one to three per cent on placebo. The great majority of those discontinuations were gastrointestinal and the great majority occurred during escalation.¹²

Those figures should be read as a floor. Trial participants receive weekly contact, free product, a nurse who can be telephoned, and an investigator with a strong interest in retention, and they are pre-selected by their willingness to enter a trial. Real-world persistence data for this class is markedly worse, with a substantial proportion of people no longer filling prescriptions at twelve months, for reasons that combine tolerability with cost and supply.

The Journal draws one inference. If most intolerance-driven discontinuation happens during escalation, and escalation practice is the least evidence-based part of the treatment course, then the largest available improvement in outcomes in this class is probably not a new molecule. It is a better answer to the titration question, which nobody has run a trial to obtain.³

When the symptom is not the molecule

Everything above assumes the vial contains the compound at the stated strength and nothing else of consequence. For licensed product that is a fair assumption. For research-grade material it is a hypothesis, and it bears directly on symptom interpretation, because a person cannot reason about tolerability if the exposure is unknown.

Three failure modes produce gastrointestinal symptoms that will be misattributed. Peptide content below the labelled figure means a person is at a lower dose than they believe, and escalating on that basis produces a larger real step than intended. Content above the labelled figure does the reverse. And bacterial endotoxin, which is not detected by any purity assay, produces systemic symptoms including nausea, chills and malaise that look nothing like a specification failure on paper.

The four independent services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — report purity routinely and content and endotoxin less consistently. Several vendors, among them WXT, SSA, CPC and SWB, now publish per-batch reports; several do not. The Journal has argued in Analytics that content and endotoxin should be standard reported fields, and the tolerability case is the strongest argument for it we know.

Five things about this effect profile nobody can answer

First, whether any symptomatic antiemetic strategy works better than placebo in this specific population. No adequately powered randomised trial exists that we can find.

Second, whether the dietary measures universally recommended have any measurable effect beyond the natural attenuation that occurs anyway at a fixed dose. Disentangling the two requires a design nobody has run.

Third, what predicts an individual tolerability ceiling. Nothing measurable at baseline does so usefully, which mirrors the situation for efficacy.

Fourth, how much of the perioperative risk is attributable to residual gastric content and how much to confounding by the conditions that lead people to these drugs. The available studies are mostly retrospective.

Fifth, whether gastrointestinal symptom burden predicts weight outcome. Analyses have looked, and the relationship is weaker than the folk model — which holds that suffering more means losing more — would predict.⁴

Readers who know of trials answering any of the five should write to standards@compoundjournal.com. We would print the correction gladly.

The management literature specific to this population is thin to the point of embarrassment. Millions of people are being advised to eat smaller meals, avoid fat and take ondansetron, on the basis of mechanism and clinical habit rather than trial. None of that advice is unreasonable and none of it has been measured here. The Journal will keep labelling the difference, and we would welcome the trial that made the labelling unnecessary.